GERN Stock - Geron Corp.

GERN Stock Chart

GERN Profile

Geron Corporation, a clinical-stage biopharmaceutical firm, specializes in advancing and bringing to market therapies targeting myeloid hematologic malignancies. The company's primary focus is on the development of imetelstat, a telomerase inhibitor currently undergoing Phase 3 clinical trials. Imetelstat is designed to counteract the excessive proliferation of malignant stem and progenitor cells implicated in hematologic myeloid malignancies. Specifically, it aims to address conditions such as low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis, potentially offering novel treatment options where conventional therapies have limitations.

Founded in 1990 and headquartered in Foster City, California, Geron Corporation leverages its extensive research and development capabilities to advance innovative therapeutic solutions in the biopharmaceutical sector. The company's commitment to pioneering treatments for complex hematologic conditions underscores its dedication to addressing critical unmet medical needs.

Geron Corporation's strategic approach integrates rigorous clinical trials and regulatory pathways to progress imetelstat toward potential regulatory approvals. By focusing on therapeutic innovation and clinical excellence, the company aims to transform the treatment landscape for patients affected by myeloid hematologic malignancies.

With a steadfast mission to improve patient outcomes through scientific advancements, Geron Corporation continues to expand its capabilities and partnerships within the biopharmaceutical industry. The company remains at the forefront of research-driven initiatives aimed at delivering impactful therapies that enhance the quality of life for individuals battling hematologic cancers.

GERN Revenue Chart

GERN Earnings

Analyst Ratings